{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:46:08Z","timestamp":1793277968136,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.radonc.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:06:05Z","timestamp":1666267565000},"page":"109380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer \u2013 Results of a large multicenter analysis"],"prefix":"10.1016","volume":"181","author":[{"given":"Johannes","family":"Roesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Wegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Trommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schleifenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"M\u00e4urer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knippen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dobiasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Waltenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"von der Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"S\u00fc\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastassia","family":"L\u00f6ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"He\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Tamaskovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vinsensia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.10.007_b0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99\u201302): an open-label phase 3 randomised trial","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0010","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.5301\/tj.5000368","article-title":"Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors","volume":"101","author":"Buglione","year":"2015","journal-title":"Tumori J"},{"key":"10.1016\/j.radonc.2022.10.007_b0020","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.radonc.2022.10.007_b0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2017.11.036","article-title":"Volume, dose, and fractionation considerations for IMRT-based reirradiation in head and neck cancer: a multi-institution analysis","volume":"100","author":"Caudell","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.radonc.2022.10.007_b0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0360-3016(89)90094-1","article-title":"Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience","volume":"17","author":"Cooper","year":"1989","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00066-015-0886-3","article-title":"Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer","volume":"192","author":"Cvek","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.10.007_b0045","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1200\/JCO.1998.16.11.3556","article-title":"Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients","volume":"16","author":"De Crevoisier","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00066-018-1400-5","article-title":"Incidence of second primary cancers after radiotherapy combined with platinum and\/or cetuximab in head and neck cancer patients","volume":"195","author":"Elicin","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.10.007_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2022.10.007_b0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.radonc.2020.01.016","article-title":"Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel\/cisplatin to standard radiotherapy with fluorouracil\/cisplatin: the PacCis-trial","volume":"144","author":"Fietkau","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hed.23865","volume":"38","author":"Ghosh-Laskar","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2022.10.007_b0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0075","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.3390\/cancers13143413","article-title":"A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer","volume":"13","author":"Hecht","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2022.10.007_b0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12885-020-07440-w","article-title":"Treatment response lowers tumor symptom burden in recurrent and\/or metastatic head and neck cancer","volume":"20","author":"Hecht","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2022.10.007_b0085","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2007.15.0102","article-title":"Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma","volume":"26","author":"Janot","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0090","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T","article-title":"Second primary tumors in patients with head and neck squamous cell carcinoma","volume":"75","author":"Jones","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.10.007_b0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"MACH-NC collaborative group, meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2006.12.055","article-title":"Salvage re-irradiation for recurrent head and neck cancer","volume":"68","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0110","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.oraloncology.2018.11.024","article-title":"Prognostic factors and selection criteria in the retreatment of head and neck cancers","volume":"88","author":"May","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2022.10.007_b0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1200\/JCO.2010.31.8311","article-title":"Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer","volume":"29","author":"Morris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/00016489.2020.1831697","article-title":"Influence of p16 status on indication and outcome of salvage neck dissection in oropharyngeal cancer","volume":"141","author":"Mueller","year":"2021","journal-title":"Acta Otolaryngol (Stockh)"},{"key":"10.1016\/j.radonc.2022.10.007_b0135","unstructured":"NCCN, 2022. National Comprehensive Cancer Network Guideline Head and Neck Cancers (Version 2.2022) [WWW Document]. URL www.nccn.org."},{"key":"10.1016\/j.radonc.2022.10.007_b0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1002\/hed.25890","article-title":"Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: a multi-institutional study of AIRO\u2014head and neck working group","volume":"41","author":"Orlandi","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2022.10.007_b0145","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.19.03156","article-title":"Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study","volume":"38","author":"Powell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0150","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","article-title":"Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis","volume":"15","author":"Pulte","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2022.10.007_b0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13014-020-01531-5","article-title":"The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer","volume":"15","author":"R\u00fchle","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0160","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijrobp.2005.07.005","article-title":"Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma","volume":"64","author":"Salama","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-019-1452-4","article-title":"Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group \u201cpersonalized radiotherapy in head and neck cancer\u201d","volume":"15","author":"Sch\u00fcttrumpf","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00066-020-01706-9","article-title":"Routine restaging after primary non-surgical treatment of laryngeal squamous cell carcinoma\u2014a review","volume":"197","author":"Seebauer","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.10.007_b0175","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/annonc\/mdq219","article-title":"Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial","volume":"21","author":"Sharma","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00106-021-01030-3","article-title":"Salvage laryngectomy after primary radio- and radiochemotherapy: a retrospective study","volume":"69","author":"Sievert","year":"2021","journal-title":"HNO"},{"key":"10.1016\/j.radonc.2022.10.007_b0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hed.20697","article-title":"Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck","volume":"30","author":"Spencer","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2022.10.007_b0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2008.04.021","article-title":"IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes","volume":"73","author":"Sulman","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.10.007_b0195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2017.04.017","article-title":"A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer","volume":"100","author":"Vargo","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.oraloncology.2017.01.007","article-title":"Re-irradiation for recurrent and second primary cancers of the head and neck","volume":"67","author":"Velez","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0205","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.10.007_b0210","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2017.06.012","article-title":"Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative","volume":"100","author":"Ward","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.10.007_b0215","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.3390\/ijms22179114","article-title":"Hypofractionated radiotherapy upregulates several immune checkpoint molecules in head and neck squamous cell carcinoma cells independently of the HPV status while ICOS-L is upregulated only on HPV-positive cells","volume":"22","author":"Wimmer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2022.10.007_b0220","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1200\/EDBK_157804","article-title":"Locoregional recurrent or second primary head and neck cancer: management strategies and challenges","author":"Wong","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022045029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022045029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:24:39Z","timestamp":1759123479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022045029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":44,"alternative-id":["S0167814022045029"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.10.007","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer \u2013 Results of a large multicenter analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109380"}}